They made an attempt last Thursday: www.ipharmi
Post# of 72440
www.ipharminc.com/press-release/2018/3/15/innovation-pharmaceuticals-views-brilacidin-om-as-clearly-differentiated-compared-to-limited-competition-for-preventing-severe-oral-mucositis
They're tooting B-OMs horn as loudly as they can but there is only so much they can say without violating CDAs.
With a market cap of just $75M we are holding some serious pipeline power in Brilacidin. It's really just a matter of faith in the deal making process at this point. We know that the Brilacidin trial results are worth more than $75M to almost any BP.
A small deal is still going to catapult us from this market cap. If we get $20M-30M upfront and a funded trial for phase 3 on B-OM + milestones we will soar. Breaking the reliance on Aspire and getting true validation will change the company over night. Just need to have faith in Leo to bring home the best deal. I believe in him.
Go IPIX!